000 02278nam a2200385 c 4500
988 _aSpringer_BiomedLife_2019
999 _c115557
_d115557
_x1
001 115557
003 ESmaUEC
005 20230110040236.0
006 a||||fo|||| 00| 0
007 cr nn nnnaamaa
008 190930s2019 gw a o |||| 0|eng d
020 _a9783319336732
024 7 _a10.1007/978-3-319-33673-2
_2doi
040 _aES-MaUEC
_bspa
_cES-MaUEC
_dES-MaUEC
050 4 _aRC271.N46
_b2019 EB
245 0 0 _aTumor Angiogenesis :
_bA Key Target for Cancer Therapy
_cedited by Dieter Marmé.
250 _a1st ed. 2019.
264 1 _aCham
_bSpringer International Publishing
_c2019
300 _a1 recurso en línea
_b63 ilustraciones, 58 ilustraciones a color
336 _aTexto
_btxt
_2rdacontent
337 _2rdamedia
_aelectrónico
_bc
338 _2rdacarrier
_arecurso electrónico
_bcr
347 _atext file
_bPDF
490 0 _aBiomedical and Life Sciences (Springer-11642)
520 3 _aThis exhaustive work shows that new therapies using anti-angiogenic drugs are of particular importance because they can be used against many different types of cancer, as tumor angiogenesis seems to be involved in most if not all solid metastasizing malignancies. The first part of this book summarizes the knowledge acquired on the molecular entities that play a role in tumor angiogenesis and their mechanisms of action. Furthermore, the identification of molecular markers and their validation as predictive and/or prognostic tools is reviewed. In the second and most important part, the clinical applications of anti-angiogenic treatments are documented for a wide variety of tumors. In particular, the modes of combination with other targeted and/or cytotoxic cancer therapies are presented.
650 7 _2embne
_aInhibidores de la neovascularización
_9671432
650 7 _2embne
_9174085
_aCáncer
_xTratamiento
650 7 _2embne
_aOncología
_9139207
700 1 _aMarmé, Dieter
_eeditor
_4edt
776 0 8 _iPrinted edition:
_z9783319336718
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-319-33673-2
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942 _2lcc
_cLE
998 _aSI
_cm
_dz
_feng
_ggw
_h0
_b11/2019
_ea
_zSI